Novo Nordisk’s Wegovy tablet, containing the active ingredient semaglutide, has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in adults with obesity or overweight conditions in the United Kingdom. The pill offers an alternative to the existing injectable version of Wegovy, which also utilizes semaglutide.
The tablet regimen begins with a daily dose of 1.5mg and gradually increases through 4mg, 9mg, and finally 25mg, with patients advised to spend at least one month on each dosage before escalating. While the dosing differs from the injectable form, patients currently on the initial Wegovy injection dose (0.25mg weekly) are likely to transition to the 4mg tablet, whereas those receiving the higher 2.4mg semaglutide injection can switch directly to the 25mg pill, with at least a one-week gap between the last injection and the first oral dose. The medication can also be used as a substitute for tirzepatide (Mounjaro), with lower-dose patients generally moving to 4mg tablets and higher-dose patients to 25mg, but all transitions require medical supervision.
Wegovy tablets must be taken on an empty stomach after a fasting period of at least eight hours, with only minimal water intake permitted. Patients must wait 30 minutes before consuming any food, beverages, or other medications. Health professionals stress that the choice between the Wegovy tablet, injectable semaglutide, or tirzepatide depends on individual circumstances, including medical history, lifestyle, and treatment objectives, underlining the importance of a thorough consultation with a prescribing professional.
The pill is authorized for adults with a body mass index (BMI) of 30 or above, or those with a BMI between 27 and 30 if they also have weight-related health conditions such as high blood pressure, prediabetes, or high cholesterol. Use of the medication must be accompanied by appropriate diet and exercise guidance, and patients are cautioned against accepting prescriptions without this support, which may indicate unreliable providers.
Users are advised to report any adverse effects to their healthcare providers and to the MHRA’s Yellow Card scheme, which monitors medication safety.
Personal accounts highlight the medication’s benefits and costs. One user, Heather, noted that although the monthly price of £113 is significant, it results in savings on food expenses due to reduced appetite and snacking. Another patient, Sharon, opted for the pill over injections because of cost considerations—the injectable’s monthly outlay could reach $500, a prohibitive amount for her family of six.
Sharon has been using Wegovy tablets following gastric sleeve surgery in early 2025, initially attaining a 4mg dose before reducing to 1.5mg to manage appetite rather than eliminate hunger completely. She reported a consistent weekly weight loss of approximately 2 pounds, ultimately reaching her target weight in May 2026. Since discontinuing the medication later that month, she is focusing on weight maintenance through exercise and lifestyle adjustments, though she acknowledges challenges with cravings and the possibility of resuming treatment if necessary.
The introduction of the Wegovy tablet expands treatment options for individuals seeking pharmaceutical support in weight management, offering flexibility in administration with a requirement for professional oversight and adherence to comprehensive lifestyle interventions.